|
Sitagliptin-induced hemolysis
Ragini Bekur, MV Nagaraja, KN Shivashankara, Weena Stanley
Department of Medicine, Kasturba Medical College, Manipal University, Manipal, India
Correspondence Address:
Ragini Bekur
Department of Medicine, Kasturba Medical College, Manipal University, Manipal
India
Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent. The advantages are the absence of hypoglycemia when used as monotherapy and they cause less gain weight. We report a case of sitagliptin-induced hemolysis, a rare side effect, not reported in the literature. As sitagliptin is widely used in type 2 diabetes mellitus physicians should be aware of the possibility of this rare but potentially serious adverse drug reaction.
How to cite this article:
Bekur R, Nagaraja M V, Shivashankara K N, Stanley W. Sitagliptin-induced hemolysis.Indian J Pharmacol 2010;42:320-321
|
How to cite this URL:
Bekur R, Nagaraja M V, Shivashankara K N, Stanley W. Sitagliptin-induced hemolysis. Indian J Pharmacol [serial online] 2010 [cited 2022 Jun 28 ];42:320-321
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2010;volume=42;issue=5;spage=320;epage=321;aulast=Bekur;type=0 |
|
